Free option on their own operations: management describes a real capability it already owns that could serve a second, m
The model's full reasoning — Q3 2018 call → NOWe need answer YES/NO based on transcript. Need identify if management describes company already owns/operates capability useful for second larger purpose and recently began turning second use into real business. We need parse transcript. Company Agios. They have TIBSOVO (ivosidenib) approved for relapsed/refractory AML. They now plan sNDA for newly diagnosed AML patients not eligible for standard therapies. But is that same drug already owned and operated? Yes, TIBSOVO already approved and launched for R/R AML. Now expanded to newly diagnosed AML. That's an existing working capability (drug, approval, commercial infrastructure, launch). Second use is larger indication? Newly diagnosed AML is larger than relapsed/refractory. They have data, plan to submit sNDA by end Jan 2019. They already have revenue from R/R AML ($4.5M). But the second use (newly diagnosed) is not yet approved/revenue? They have not begun converting? They submitted plan? They have FDA real-time oncology review, but no revenue yet for newly diagnosed. Need answer NO because second use is not yet real business, contingent on sNDA approval. However transcript also mentions "expanding indications" and "newly diagnosed AML patients not eligible for standard therapies" - but that's future. Also "Both of our IDH inhibitors now available to patients" - IDHIFA is from Celgene. TIBSOVO launch. Another possible capability: IDHIFA won Prix Galien. But no. Question asks: "does management describe that SOMETHING THE COMPANY ALREADY OWNS AND ALREADY OPERATES FOR ITS EXISTING BUSINESS HAS TURNED OUT TO BE USEFUL FOR A SECOND, MUCH LARGER PURPOSE — and that the company has recently BEGUN turning that second use into real business, without having had to build a new company to do it?" Need conditions. Could be pyruvate kinase activation in other anemias: mitapivat for PK deficiency (pivotal trials) and thalassemia (Phase 2 proof-of-concept to start by end of year). Existing capability is drug and clinical program? Second use thalassemia maybe larger. But not yet converting; just starting trial. Could be AG-881 pan-IDH inhibitor gained worldwide rights from Celgene, for solid tumors. Existing capability? They have IDH inhibitors, now AG-881 for low-grade glioma. But not yet business. Could be TIBSOVO for cholangiocarcinoma (solid tumor) - Phase 3 CLARITY enrolling. Not yet approved. Could be MDS. Not.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| HCKT | The Hackett Group, Inc. | Q1 2024 | 2024-05-08 | C |
| HUYA | HUYA Inc. | Q4 2023 | 2024-03-19 | C |
| SANG | Sangoma Technologies Corporation | Q2 2024 | 2024-02-08 | D |
| QTRX | Quanterix Corporation | Q3 2023 | 2023-11-07 | B |
| OPAD | Offerpad Solutions Inc. | Q3 2023 | 2023-11-01 | C |
| APPS | Digital Turbine, Inc. | Q1 2024 | 2023-08-08 | D |
| GGR | Gogoro Inc. | Q1 2023 | 2023-05-11 | D |
| VNRX | VolitionRx Limited | Q1 2022 | 2022-05-12 | F |
| RELY | Remitly Global, Inc. | Q4 2021 | 2022-03-02 | B |
| PRPO | Precipio, Inc. | Q3 2018 | 2018-11-19 | D |
HCKT · Q1 2024 → YESThe question is about whether management describes something the company already owns and operates that has turned out useful for a second, much larger purpose, and they've begun turning that into rea...
HUYA · Q4 2023 → YESThe question is whether management describes something the company already owns and operates that has turned out useful for a second, much larger purpose, and they've begun turning that into real busi...
SANG · Q2 2024 → YESThe question is about whether management describes something the company already owns and operates that has turned out useful for a second, much larger purpose, and they've begun turning that into rea...